t
On 26 August 2026, Oxford BioDynamics Plc announced that resolutions at its General Meeting were passed, and an application was made for 9,150,000,000 new Ordinary Shares of £0.001 each to be admitted to trading on AIM. Admission is expected on 27 August 2026, resulting in a total issued ordinary share capital of 13,440,910,967 Ordinary Shares. Directors Martin Diggle, Richard Compton, Iain Ross, Dr. Alexandre Akoulitchev, and Paul Stockdale acquired a combined 955,000,000 new Ordinary Shares at £0.001 each on 26 August 2026.
| Date | 26 Aug 2026 |
| Time | 11:50:00 |
| Category | AGMs and other meetings |
| ID | 2666S |
26 August 2026
Oxford BioDynamics Plc
("OBD" or the "Company")
Result of General Meeting and Total Voting Rights
Director/PDMR Dealings
Oxford, UK - 26 August 2026 - Oxford BioDynamics Plc (AIM: OBD), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and biotech partners, announces that the resolutions proposed at the General Meeting of the Company, held earlier today, pursuant to the Placing announced on 10 August 2026, were duly passed.
Accordingly, an application has been made to the London Stock Exchange for 9,150,000,000 new Ordinary Shares of £0.001 each in the capital of the Company, to be admitted to trading on AIM.
It is expected that Admission will take place, and trading in the Placing Shares will commence, at 8.00 a.m. on 27 August 2026. Following Admission, the Company's issued ordinary share capital and total voting rights will consist of 13,440,910,967 Ordinary Shares. This figure should be used by shareholders as the denominator for the calculation by which they determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The total new Ordinary Shares subscribed for pursuant to the Placing by the Directors and PDMRs who are participating in the Placing, are set out below:
|
Director/PDMR |
Existing beneficial shareholding |
Placing Shares |
Beneficial shareholding following the Placing |
Shareholding as a percentage of the Enlarged Ordinary Share Capital |
|
Martin Diggle1 |
618,542,844 |
500,000,000 |
1,118,542,844 |
8.32% |
|
Richard Compton |
0 |
300,000,000 |
300,000,000 |
2.2% |
|
Iain Ross |
23,333,333 |
100,000,000 |
123,333,333 |
0.9% |
|
Dr. Alexandre Akoulitchev |
14,228,962 |
30,000,000 |
44,228,962 |
0.3% |
|
Paul Stockdale |
6,411,252 |
25,000,000 |
31,411,252 |
0.2% |
1 Martin Diggle's beneficial holding is held through the Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are controlled by him.
Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the Circular published on 10 August 2026.
For further information please contact:
|
Oxford BioDynamics Plc Iain Ross, Non-Executive Chairman Richard Compton, CEO Paul Stockdale, CFO
|
+44 (0)1865 518910 |
|
Singer Capital Markets - Nominated Adviser and Broker Alex Bond / Russell Cook / Anastassiya Eley
|
+44 (0)20 7496 3000 |
|
OAK Securities - Joint Broker Matthew Clarke / Jerry Keen
|
+44 (0)20 3973 3678 |
|
Camarco - Financial PR Marc Cohen / Sukaina Virji / Tilly Butcher / Fergus Young |
+44 (0)20 3757 4980
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||||||||
|
a) |
Name |
1) Iain Ross 2) Richard Compton 3) Dr. Alexandre Akoulitchev 4) Paul Stockdale 5) Martin Diggle |
||||||||||||||||||
|
2 |
Reason for the notification |
|||||||||||||||||||
|
a) |
Position/status |
1) Non-Executive Chairman 2) Chief Executive Officer 3) Chief Scientific Officer 4) Chief Financial Officer 5) Non-Executive Director |
||||||||||||||||||
|
b) |
Initial notification / Amendment |
Initial Notification |
||||||||||||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||||
|
a) |
Name |
Oxford BioDynamics Plc |
||||||||||||||||||
|
b) |
LEI |
2138005Y1TK258O5U928 |
||||||||||||||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of £0.001 each ISIN: GB00BD5H8572 |
||||||||||||||||||
|
b) |
Nature of the transaction |
Purchase of ordinary shares |
||||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||||
|
d) |
Aggregated information |
N/A - each a single transaction |
||||||||||||||||||
|
e) |
Date of the transaction |
26 August 2026 |
||||||||||||||||||
|
f) |
Place of the transaction |
London Stock Exchange, AIM (AIMX) |
||||||||||||||||||